Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index; 93 of the 166 sources its claims cite were checked for support.
Abstract
Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders. Acute and chronic activation of GLP-1 receptor signaling also reduces systemic and tissue inflammation in mice and humans, through weight loss-dependent and -independent mechanisms, actions that may contribute to the expanding spectrum of clinical benefits ascribed to GLP-1 medicines. In this Review, we highlight current understanding of the direct and indirect antiinflammatory effects and mechanisms of GLP-1 medicines in both preclinical and clinical studies, covering emerging concepts, clinical relevance, and areas of uncertainty that require further investigation.
Overview
CoChat Summary
TL;DR
This review argues that GLP-1-based therapies have antiinflammatory effects beyond their metabolic benefits, with evidence from preclinical and clinical studies across many organ systems. It also highlights that both direct immune-cell actions and indirect neural/metabolic mechanisms likely contribute, but the relative importance of each remains uncertain.
Key findings
- GLP-1 medicines lower inflammatory biomarkers in people with T2D and/or obesity, including plasma CRP; in semaglutide SUSTAIN and PIONEER trials, glucose and weight explained only 20%–60% of the observed CRP reductions.
- In preclinical models, acute GLP-1R agonism reduces inflammation independent of major weight loss, for example exenatide or semaglutide reduced circulating TNF-α in LPS-challenged mice, and exenatide downregulated TNF and IL1B in human PBMCs.
- The review highlights organ-specific antiinflammatory signals: in osteoarthritis, semaglutide improved WOMAC score by –41.7 points versus –27.5 with placebo in STEP-9; in MASH, semaglutide resolved steatohepatitis without worsening fibrosis in 63% versus 34% with placebo, and improved fibrosis without worsening steatohepatitis in 37% versus 23%.
- Clinical kidney data also support antiinflammatory/anti-fibrotic benefit: in FLOW, once-weekly 1 mg semaglutide reduced the primary composite risk by 24% and delayed CKD progression over 4 years.
Methods
- Narrative review synthesizing preclinical and clinical evidence on GLP-1 medicines and inflammation across intestinal, cardiovascular, liver, kidney, pulmonary, arthritis, and neuroinflammatory contexts.
- Draws on mouse models, human cell experiments, knockout/lineage-tracing studies, and randomized clinical trials and post hoc analyses; no new primary dataset is reported in the text provided.
- Main analytic approach is comparative interpretation of direct versus indirect antiinflammatory mechanisms, including weight loss–dependent and weight loss–independent effects.
Limitations
- The paper states that distinguishing metabolic from non-metabolic antiinflammatory effects will require complementary transgenic models, pair-feeding experiments, and interdisciplinary techniques; this indicates that current evidence is not sufficient to isolate mechanisms.
- Several mechanistic claims are explicitly uncertain, including the role of specific GLP-1R-expressing cells in heart, lung, liver, kidney, and brain, and whether neural mechanisms explain human biomarker changes.
- Evident from the text: this is a review, so conclusions depend on the quality and heterogeneity of prior studies rather than a single controlled experiment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
78 Valid · 3 Not valid · 49 Not checked · 22 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Both mouse and human endocardial endothelial cells express Glp1r/GLP1R (57).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1 medicines in cardiovascular inflammation
What the sources say
- Disputedcites [57] sourceExperimental — accuracy not yet measured
The Results report Glp1r expression in mouse endocardial endothelial cells, but say human endocardial endothelial cells did not co-localize with GLP1R expression. The Discussion describes this as a species-specific difference. The Conclusions and limitations caution that human endocardial cells were underrepresented in the datasets, limiting detection; the paper therefore does not establish their expression of GLP1R. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Administration of LPS, an endotoxin derived from Gram-negative bacteria that activates innate immunity and increases proinflammatory cytokines such as TNF-α, IL-6, and IL-1β, elevates circulating GLP-1 within 3 hours in mice and humans (5–7).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1–producing L cells as pathogen and inflammation sensors
What the sources say
- Not checked — no full text of the sourcecites [5] source
- Supportedcites [6] source
Figure 2 (p. 5) reports plasma GLP-1 measurements 3 hours after LPS injection in mice, and the results (p. 4) state that LPS induced circulating GLP-1. The human results (p. 6) report increased plasma GLP-1 3 hours after LPS injection, compared with saline. (LLM, conf=0.93)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Results section reports increased plasma GLP-1 in mice after LPS injection, with measurements at 3 hours (Figure 3). It also says prior evidence links LPS administration to increased GLP-1 secretion in mice and humans, but our copy does not establish the 3-hour timing in humans. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Both LPS- and IL-1β–induced GLP-1 release partly depends on IL-6 as shown in Il6–/– mice (5, 6), although the source of IL-6 that triggers L cells is unclear.”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1–producing L cells as pathogen and inflammation sensors
What the sources say
- Not checked — no full text of the sourcecites [5] source
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
In “LPSs Induce GLP-1 Secretion through a TLR4Dependent Pathway” (p. 4), LPS caused an attenuated but detectable increase in GLP-1 secretion in Il6-deficient mice, supporting partial IL-6 dependence for the LPS response. The passages do not establish the same result for IL-1β-induced release in Il6-deficient mice. (LLM, conf=0.88)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In humans, LPS infusion raises GLP-1 levels in healthy young subjects (9).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1–producing L cells as pathogen and inflammation sensors
What the sources say
- Partly supportedcites [9] sourceExperimental — accuracy not yet measured
The Conclusion reports elevated GLP-1 after dual LPS exposure, and the Discussion identifies the participants as healthy young men. The claim omits the prolonged, dual-exposure condition: the Discussion also notes that GLP-1 decreased during the first six hours of LPS exposure in a separate study of healthy young men. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“For example, a single dose of exenatide or semaglutide reduced circulating TNF-α levels in mice challenged with LPS (21, 22).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > Weight loss–independent antiinflammatory effects of GLP-1 medicines
What the sources say
- Supportedcites [21] source
The Methods describe a single subcutaneous dose of semaglutide before an LPS challenge in mice. The Results report that semaglutide reduced plasma TNF-α at both 1 and 4 hours. This source supports the semaglutide part of the jointly cited sentence; it does not test exenatide. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [22] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
88 more claims · 43 with their cited sources checked
Create a free account to see all 152 claims and every source verdict.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti‐inflammatory cytokines such as IL‐4 and IL‐10, together with additional metabolic mediators and adipokines including ghrelin, may provide complementary insight into the counter‐regulatory and immunometabolic effects of incretin‐based therapies in T2DM [65]”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [65]
Experimental — accuracy not yet measured
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · cited 1×
“…have not been attributed to GLP-1 action in specific organs or cell types, the kidney GLP-1R has been localized primarily to vascular smooth muscle cells within renal arteries and arterioles using either 125 I-labeled exendin-4, a validated anti–GLP-1R antibody, or in situ hybridization (71, 72).”
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“In parallel, daily treat-ment with 50 μ g/kg liraglutide for 20 weeks improved urine chemistry and podocyte histology in Ins2 Akita mice, a transgenic model of spontaneous diabetes.”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 2×
“In parallel, daily treat-ment with 50 μ g/kg liraglutide for 20 weeks improved urine chemistry and podocyte histology in Ins2 Akita mice, a transgenic model of spontaneous diabetes.”
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“Multiple GLP-1 medicines, including exenatide (15), liraglutide (16), semaglutide (17, 18), and tirzepatide (19), reduce plasma CRP levels in people living with T2D and/or obesity.”
Colchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299 · cited 1×
“…have not been attributed to GLP-1 action in specific organs or cell types, the kidney GLP-1R has been localized primarily to vascular smooth muscle cells within renal arteries and arterioles using either 125 I-labeled exendin-4, a validated anti–GLP-1R antibody, or in situ hybridization (71, 72).”
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 1×
“…bowel disease (85), further research is needed to understand the significance of the GLP-1R downregulation during inflammatory bowel disease and how GLP-1 medicines interact with inflammatory bowel disease through both metabolic improvements and direct antiinflammatory actions on the intestine.”
Hallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789 · cited 1×
“Neuroinflammation is a hallmark of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases (45).”
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 1×
“Whether the renal arterial GLP-1R mediates the antiinflammatory actions of GLP-1 medicines in the kidney remains to be determined.”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123 · cited 2×
“Twice-weekly treatment with 3 mg/kg of the PEGylated exenatide NLY01 for 5 months reduced IL-1 α , TNF-α , and C1q secretion by primary mouse microglia exposed to α -synuclein preformed fibrils, thereby limiting astrocyte conversion to the neurotoxic A1 phenotype (46).”
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413258 · Cited by 1,115 · cited 1×
“of GLP-1 medicines may contribute to or be independently associated with their benefits in OSA.”
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 2×
“While these benefits for neurodegeneration may involve antiinflammatory actions, direct attribution to such effects remains to be conclusively demonstrated.”
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648 · cited 1×
“…that obesity is a common comorbidity of inflammatory bowel disease (85), further research is needed to understand the significance of the GLP-1R downregulation during inflammatory bowel disease and how GLP-1 medicines interact with inflammatory bowel disease through both metabolic improvements…”
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583
Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533 · cited 1×
“of GLP-1 medicines may contribute to or be independently associated with their benefits in OSA.”
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0883 · Cited by 463 · cited 1×
“In PIONEER 2, oral semaglutide reduced CRP by 30%, whereas empagliflozin had no effect despite similar approximately 4% weight loss (24).”
Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes
Singh, S., Dulai, P. S., Zarrinpar, A., Ramamoorthy, S., & Sandborn, W. J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.181 · Cited by 452 · cited 1×
“Given that obesity is a common comorbidity of inflammatory bowel disease (85), further research is needed to understand the significance of the GLP-1R downregulation during inflammatory bowel disease and how GLP-1 medicines interact with inflammatory bowel disease through both metabolic…”
Wei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450 · cited 1×
“The precise localization of GLP-1R expression in human lungs remains unclear (78).”
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403664 · Cited by 440
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383 · cited 1×
“Concerns regarding pancreatitis have not been substantiated in large cardiovascular outcome trials (92, 93).”
Self-citationA body–brain circuit that regulates body inflammatory responses
Jin, H., Li, M., Jeong, E., Castro-Martinez, F., & Zuker, C. S. (2024) · Nature · doi:10.1038/s41586-024-07469-y · Cited by 383 · cited 1×
“This is particularly relevant given the role of the brain stem in regulating the vagal pathway and the cholinergic antiinflammatory reflex (14), suggesting a possible yet under-investigated neuroimmune link.”
Trial of Lixisenatide in Early Parkinson’s Disease
Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312323 · Cited by 369 · cited 1×
“While these benefits for neurodegeneration may involve antiinflammatory actions, direct attribution to such effects remains to be conclusively demonstrated.”
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · cited 2×
“The limited specificity of many antibodies against mouse and human GLP-1R, combined with the challenges of detecting the receptor at low abundance, has been well documented (37, 39, 40).”
Self-citationFrias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01163-7 · Cited by 334
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319 · cited 1×
“…GLP-1R expression in peripheral tissues is generally low and restricted to rare cell types (26), antiinflammatory benefits have been observed in various preclinical models, such as obesity, atherosclerosis, steatohepatitis, and nephritis, even in the absence of direct immune cell targeting (27–32).”
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315 · cited 1×
“Phase II trials for tirzepatide and survodutide, a GLP-1/ glucagon receptor co-agonist, have also shown positive outcomes in people living with MASH and obesity, demonstrating reduction of inflammation without worsening of fibrosis (4, 69).”
GLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312 · cited 5×
“Therefore, accurate detection of GLP-1R requires combined approaches, including full-length Glp1r / GLP1R cDNA detection, in situ hybridization, and anti-body-based methods validated with knockout controls.”
InfluentialSelf-citationWang, L., Xu, R., Kaelber, D. C., & Berger, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21305 · Cited by 304
Wong, C. K., McLean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R., Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. J., & Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.11.009 · Cited by 304 · cited 8×
“For example, in Glp1r Nes–/– mice, semaglutide loses its acute antiinflammatory effects against LPS-induced inflammation, yet tirzepatide still effectively prevents TNF-α induction, suggesting that tirzepatide does not rely exclusively on neuronal GLP-1R to exert this effect (22).”
InfluentialSelf-citationRevisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289 · cited 2×
“GLP-1 medicines regulate inflammation partly by directly modulating immune cells, although GLP-1R expression is typically low in lymphoid organs (Figure 1) (26).”
Self-citationExenatide Exerts a Potent Antiinflammatory Effect
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284 · cited 4×
“Thymus, bone marrow, spleen, mesenteric lymph nodes, brachial/axillary lymph nodes, inguinal lymph nodes, and PBMCs express low levels of Glp1r (29, 33, 34).”
InfluentialHelmstädter, J., Frenis, K., Filippou, K., Grill, A., Dib, M., Kalinovic, S., Pawelke, F., Kus, K., Kröller-Schön, S., Oelze, M., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000615456.97862.30 · Cited by 283 · cited 3×
“Glp1r expression is undetectable by quantitative PCR in peritoneal or adipose tissue macrophages (37), although Lyz2 -Cre–driven deletion of Glp1r ( Glp1r Lyz2–/– ) abolishes expression in bone marrow–derived macrophages (38).”
Self-citationYusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282 · cited 4×
“Thymus, bone marrow, spleen, mesenteric lymph nodes, brachial/axillary lymph nodes, inguinal lymph nodes, and PBMCs express low levels of Glp1r (29, 33, 34).”
InfluentialSelf-citationTrevaskis, J. L., Griffin, P. S., Wittmer, C., Neuschwander-Tetri, B. A., Brunt, E. M., Dolman, C. S., Erickson, M. R., Napora, J., Parkes, D. G., & Roth, J. D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00476.2011 · Cited by 277 · cited 1×
“…with 30 μ g/kg AC3174, an exenatide analog, administered via an osmotic pump for 28 days in Lep ob mice on a high– trans -fat diet significantly reduced liver weight, hepatic lipid accumulation, and plasma alanine transaminase levels in comparison with pair-fed, weight-matched controls (30).”
Noyan-Ashraf, M. H., Shikatani, E. A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.-K., Volchuk, A., Robinson, L. A., Billia, F., Drucker, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.091215 · Cited by 259 · cited 1×
“…GLP-1R expression in peripheral tissues is generally low and restricted to rare cell types (26), antiinflammatory benefits have been observed in various preclinical models, such as obesity, atherosclerosis, steatohepatitis, and nephritis, even in the absence of direct immune cell targeting (27–32).”
Self-citationEnteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion
Lebrun, L. J., Lenaerts, K., Kiers, D., Pais de Barros, J.-P., Le Guern, N., Plesnik, J., Thomas, C., Bourgeois, T., Dejong, C. H. C., Kox, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.008 · Cited by 238
Self-citationKahles, F., Meyer, C., Möllmann, J., Diebold, S., Findeisen, H. M., Lebherz, C., Trautwein, C., Koch, A., Tacke, F., Marx, N., et al. (2014) · Diabetes · doi:10.2337/db14-0100 · Cited by 212
Endothelial-Specific Cre Mouse Models: Is Your Cre CREdibile?
Payne, S., De Val, S., & Neal, A. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.309669 · Cited by 196
McClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193 · cited 3×
“In 7-month-old APP/PS1 mice, a transgenic model of Alzheimer’s disease that expresses the human version of the amyloid polypeptide and a mutant presenilin-1, two months of daily 100 μ g/kg liraglutide treatment improved memory function as measured by object recognition and Morris water maze tests, reduced amyloid plaq…”
InfluentialHogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191 · cited 2×
“In humans, GLP-1R immunoreactivity has been detected in T cells by flow cytometry, including in invariant natural killer T (iNKT) cells (43), PBMC T cells (36), and chimeric antigen receptor (CAR) T cells (44).”
InfluentialVijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02808-3 · Cited by 181 · cited 1×
“Thus, while endocardial endothelial cells represent a plausible target for the antiinflammatory actions of GLP-1 medicines locally in both species, these medicines may also exert cardioprotective effects directly on human cardiomyocytes.”
Timper, K., del Río-Martín, A., Cremer, A. L., Bremser, S., Alber, J., Giavalisco, P., Varela, L., Heilinger, C., Nolte, H., Trifunovic, A., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.05.001 · Cited by 170 · cited 1×
“Additionally, mouse astrocytes express GLP-1R (48).”
Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166 · cited 1×
“Lymphoid cells express Glp1r more often than myeloid cells (35), with tissue-resident lymphocyte subsets showing stronger expression.”
Self-citationOsteoarthritis treatment via the GLP-1–mediated gut-joint axis targets intestinal FXR signaling
Yang, Y., Hao, C., Jiao, T., Yang, Z., Li, H., Zhang, Y., Zhang, W., Doherty, M., Sun, C., Yang, T., et al. (2025) · Science · doi:10.1126/science.adt0548 · Cited by 160
Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., & Berenbaum, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-05323-7 · Cited by 160 · cited 1×
“Recent clinical trials”
The Glucagon-Like Peptide-1 Receptor—or Not?
Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154 · cited 2×
“The limited specificity of many antibodies against mouse and human GLP-1R, combined with the challenges of detecting the receptor at low abundance, has been well documented (37, 39, 40).”
McGarry, A., Rosanbalm, S., Leinonen, M., Olanow, C. W., To, D., Bell, A., Lee, D., Chang, J., Dubow, J., Dhall, R., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00378-2 · Cited by 153 · cited 1×
“While these benefits for neurodegeneration may involve antiinflammatory actions, direct attribution to such effects remains to be conclusively demonstrated.”
Sourris, K. C., Ding, Y., Maxwell, S. S., Al-sharea, A., Kantharidis, P., Mohan, M., Rosado, C. J., Penfold, S. A., Haase, C., Xu, Y., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.029 · Cited by 143 · cited 1×
“…a diabetes-driven kidney disease model, Glp1r –/– mice with streptozotocin-induced diabetes exhibited spontaneous kidney dysfunction and accelerated kidney damage as evidenced by their higher albumin-to-creatinine ratios, increased fibronectin levels, and lower cystatin C levels in the urine (70).”
Self-citationJensen, E. P., Poulsen, S. S., Kissow, H., Holstein-Rathlou, N.-H., Deacon, C. F., Jensen, B. L., Holst, J. J., & Sorensen, C. M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00527.2014 · Cited by 141 · cited 1×
“…have not been attributed to GLP-1 action in specific organs or cell types, the kidney GLP-1R has been localized primarily to vascular smooth muscle cells within renal arteries and arterioles using either 125 I-labeled exendin-4, a validated anti–GLP-1R antibody, or in situ hybridization (71, 72).”
Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice
Song, Y., Koehler, J. A., Baggio, L. L., Powers, A. C., Sandoval, D. A., & Drucker, D. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.009 · Cited by 140
Self-citationWong, C. K., Yusta, B., Koehler, J. A., Baggio, L. L., McLean, B. A., Matthews, D., Seeley, R. J., & Drucker, D. J. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.08.003 · Cited by 138 · cited 14×
“In mice lacking Glp1r in the Lck expression domain ( Glp1r Lck–/– ), Glp1r expression is abolished in multiple IEL subsets, including CD8 αα + T-CR αβ + and CD8 αβ + TCR αβ + IELs, with an approximately 50% reduction observed in CD8 αα + TCR γδ + IELs (34).”
InfluentialSelf-citationInterleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control
Lang Lehrskov, L., Lyngbaek, M. P., Soederlund, L., Legaard, G. E., Ehses, J. A., Heywood, S. E., Wewer Albrechtsen, N. J., Holst, J. J., Karstoft, K., Pedersen, B. K., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.008 · Cited by 135
Wang, Y., Parlevliet, E. T., Geerling, J. J., van der Tuin, S. J. L., Zhang, H., Bieghs, V, Jawad, A. H. M., Shiri‐Sverdlov, R., Bot, I., de Jager, S. C. A., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12490 · Cited by 126 · cited 1×
“…high-fat diet that promotes atherosclerosis, 4 weeks of daily 50 μ g/kg exenatide treatment protected against hepatic inflammation, as indicated by a decrease in CD68 + , F4/80 + , and CD18 + /CD11b + staining, as well as reduced Tnf , Il1b , and Il6 mRNA levels in the liver (67).”
Somm, E., Montandon, S. A., Loizides-Mangold, U., Gaïa, N., Lazarevic, V., De Vito, C., Perroud, E., Bochaton-Piallat, M.-L., Dibner, C., Schrenzel, J., et al. (2021) · Translational Research · doi:10.1016/j.trsl.2020.07.008 · Cited by 118
Heiss, C. N., Mannerås-Holm, L., Lee, Y. S., Serrano-Lobo, J., Håkansson Gladh, A., Seeley, R. J., Drucker, D. J., Bäckhed, F., & Olofsson, L. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109163 · Cited by 114 · cited 1×
“Microbiota depletion in HFD-fed mice elevates plasma GLP-1 levels and attenuates hypothalamic inflammation, actions that require the astrocyte GLP-1R (49).”
Self-citationGLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation
Bang-Berthelsen, C. H., Holm, T. L., Pyke, C., Simonsen, L., Søkilde, R., Pociot, F., Heller, R. S., Folkersen, L., Kvist, P. H., Jackerott, M., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000847 · Cited by 111 · cited 1×
“Future research will help clarify whether the affinity of tirzepatide for both GLP-1R and GIPR might contribute to distinct antiinflammatory effects in clinical settings.”
Verma, S., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Jensen, C., Kandler, K., Kushner, R. F., Rubino, D. M., & Kosiborod, M. N. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101737 · Cited by 106 · cited 1×
“Multiple GLP-1 medicines, including exenatide (15), liraglutide (16), semaglutide (17, 18), and tirzepatide (19), reduce plasma CRP levels in people living with T2D and/or obesity.”
Chiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104 · cited 1×
“Notably, GLP-1R expression in gut IELs is significantly lower in the colon than in the small intestine (33), suggesting that other cell types, such as enteric neurons (82), may contribute to the antiinflammatory actions of GLP-1 medicines in the colon.”
Self-citationGlucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule
Ben Nasr, M., Usuelli, V., Dellepiane, S., Seelam, A. J., Fiorentino, T. V., D’Addio, F., Fiorina, E., Xu, C., Xie, Y., Balasubramanian, H. B., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.001 · Cited by 102 · cited 2×
“While these benefits for neurodegeneration may involve antiinflammatory actions, direct attribution to such effects remains to be conclusively demonstrated.”
GLP-1 based therapies and disease course of inflammatory bowel disease
Villumsen, M., Schelde, A. B., Jimenez-Solem, E., Jess, T., & Allin, K. H. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.100979 · Cited by 97 · cited 7×
“Cardiovascular outcome trials show that treatment with long-acting GLP-1 medicines such as liraglutide, dulaglutide, and sema-glutide reduces cardiovascular events in people living with T2D and with semaglutide also in people living with obesity (60–62).”
InfluentialMosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01585-7 · Cited by 91 · cited 2×
“Multiple GLP-1 medicines, including exenatide (15), liraglutide (16), semaglutide (17, 18), and tirzepatide (19), reduce plasma CRP levels in people living with T2D and/or obesity.”
Proteomic changes upon treatment with semaglutide in individuals with obesity
Maretty, L., Gill, D., Simonsen, L., Soh, K., Zagkos, L., Galanakis, M., Sibbesen, J., Iglesias, M. T., Secher, A., Valkenborg, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03355-2 · Cited by 86
McLean, B. A., Wong, C. K., Kaur, K. D., Seeley, R. J., & Drucker, D. J. (2021) · JCI Insight · doi:10.1172/jci.insight.153732 · Cited by 84
Self-citationMcLean, B. A., Wong, C. K., Kabir, M. G., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101641 · Cited by 82 · cited 6×
“Therefore, accurate detection of GLP-1R requires combined approaches, including full-length Glp1r / GLP1R cDNA detection, in situ hybridization, and anti-body-based methods validated with knockout controls.”
InfluentialSelf-citationGIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9
Mantelmacher, F. D., Zvibel, I., Cohen, K., Epshtein, A., Pasmanik-Chor, M., Vogl, T., Kuperman, Y., Weiss, S., Drucker, D. J., Varol, C., et al. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0001-z · Cited by 70
Self-citationPanaro, B. L., Yusta, B., Matthews, D., Koehler, J. A., Song, Y., Sandoval, D. A., & Drucker, D. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.100990 · Cited by 67
Self-citationMoschovaki Filippidou, F., Kirsch, A. H., Thelen, M., Kétszeri, M., Artinger, K., Aringer, I., Schabhüttl, C., Mooslechner, A. A., Frauscher, B., Pollheimer, M., et al. (2020) · The American Journal of Pathology · doi:10.1016/j.ajpath.2019.10.008 · Cited by 66 · cited 1×
“These effects correlated with reduced crypt cell apoptosis, as indicated by decreased cleaved caspase-3 staining.”
Self-citationGLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease
Lebherz, C., Schlieper, G., Möllmann, J., Kahles, F., Schwarz, M., Brünsing, J., Dimkovic, N., Koch, A., Trautwein, C., Flöge, J., et al. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.03.010 · Cited by 65
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
Scirica, B. M., Lincoff, A. M., Lingvay, I., Bogdanski, P., Buscemi, S., Colhoun, H., Craciun, A.-E., Ezhov, M., Hardt-Lindberg, S., Kleist Jeppesen, O., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.007 · Cited by 51
Forny Germano, L., Koehler, J. A., Baggio, L. L., Cui, F., Wong, C. K., Rittig, N., Cao, X., Matthews, D., & Drucker, D. J. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102019 · Cited by 50 · cited 1×
“Ongoing phase III trials of semaglutide for Alzheimer’s disease (EVOKE/EVOKE+) will offer further insights into whether newer GLP-1 medicines may protect against Alzheimer’s disease.”
Self-citationBrakenridge, S. C., Moore, F. A., Mercier, N. R., Cox, M., Wu, Q., Moldawer, L. L., Mohr, A. M., Efron, P. A., & Smith, S. R. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2019.04.014 · Cited by 46
Gorelik, Y., Ghersin, I., Lujan, R., Shlon, D., Loewenberg Weisband, Y., Ben-Tov, A., Matz, E., Zacay, G., Dotan, I., Turner, D., et al. (2025) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjae160 · Cited by 41 · cited 1×
“Retrospective cohort studies suggest that the use of GLP-1 medicines is associated with improved inflammatory bowel disease outcomes in people with T2D (83, 84).”
Zhou, W., Shao, W., Zhang, Y., Liu, D., Liu, M., & Jin, T. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00292.2020 · Cited by 36
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
Pujadas, G., Baggio, L. L., Kaur, K. D., McLean, B. A., Cao, X., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101586 · Cited by 34
Self-citationZhou, L., Xu, Z., Oh, Y., Gamuyao, R., Lee, G., Xie, Y., Cho, H., Lee, S., & Duh, E. J. (2021) · JCI Insight · doi:10.1172/jci.insight.93382 · Cited by 34 · cited 1×
“A 1-hour pretreatment with 1 μ M NLY01 blocked nuclear translocation of NF-κ B in LPS-stimulated primary mouse microglia (47).”
Tuttle, K. R., Wilson, J. M., Lin, Y., Qian, H.-R., Genovese, F., Karsdal, M. A., Duffin, K. L., & Botros, F. T. (2023) · American Journal of Nephrology · doi:10.1159/000529374 · Cited by 31 · cited 1×
“A follow-up post hoc analysis identified improvements in fibrosis-related biomarkers in the dulaglutide group, including lower serum PRO-C6 levels for type VI collagen formation and higher urine C3M levels for type III collagen degradation (74).”
He, W., Wei, J., Liu, X., Zhang, Z., Huang, R., & Jiang, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-62465-6 · Cited by 30 · cited 1×
“…which causes pressure overload, ventricular compensation, and heart failure, studies have reported improvements with GLP-1 medicines in ventricular hypertrophy associated with reduced inflammation in rodents (58, 59), although none of these studies addresses the potential site(s) of GLP-1 action.”
Sato, T., Shimizu, T., Fujita, H., Imai, Y., Drucker, D. J., Seino, Y., & Yamada, Y. (2020) · Endocrinology · doi:10.1210/endocr/bqaa201 · Cited by 29 · cited 3×
“In this model, Glp1r –/– mice exhibited reduced weight loss and lowered lung Il6 , Il1b , Ccl2 , and Cxcl2 expression, although survival remained unchanged (77).”
InfluentialSelf-citationGlucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice
Hammoud, R., Kaur, K. D., Koehler, J. A., Baggio, L. L., Wong, C. K., Advani, K. E., Yusta, B., Efimova, I., Gribble, F. M., Reimann, F., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174825 · Cited by 24
Self-citationGharagozloo, M., Galleguillos, D., Jank, L., Sotirchos, E. S., Smith, M. D., Garton, T., Kumar, S., Hussein, O., Potluri, S., Taylor, M., et al. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01390-4 · Cited by 23 · cited 1×
“While these benefits for neurodegeneration may involve antiinflammatory actions, direct attribution to such effects remains to be conclusively demonstrated.”
Akhtar, A., Shakir, M., Ansari, M. S., Divya, Faizan, M. I., Chauhan, V., Singh, A., Alam, R., Azmi, I., Sharma, S., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102021 · Cited by 21 · cited 1×
“In humans, GLP-1R immunoreactivity has been detected in T cells by flow cytometry, including in invariant natural killer T (iNKT) cells (43), PBMC T cells (36), and chimeric antigen receptor (CAR) T cells (44).”
Reassessment of antibody-based detection of the murine T cell GLP-1 receptor
Wong, C. K., Yusta, B., Tong, J. C. L., Broichhagen, J., Hodson, D. J., & Drucker, D. J. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.06.012 · Cited by 14 · cited 1×
“T cells (41).”
Self-citationDecreased expression of the GLP-1 receptor after segmental artery injury in mice
Bjørnholm, K. D., Povlsen, G. K., Ougaard, M. E., Pyke, C., Rakipovski, G., Tveden-Nyborg, P., Lykkesfeldt, J., & Skovsted, G. F. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0608 · Cited by 10 · cited 1×
“Interestingly, in colonic mucosal biopsies from individuals with inflammatory bowel disease, these genes were upregulated in inflamed tissue compared with noninflamed mucosa from the same patients, while GLP1R expression was downregulated.”
GLP-1R signaling does not modify the severity of experimental graft versus host disease
Yusta, B., Wong, C. K., Matthews, D., Koehler, J. A., Baggio, L. L., Bang, K. W. A., & Drucker, D. J. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102235 · Cited by 7
Self-citationThe Effect of Weight Loss on C-Reactive Protein: A Systematic Review
Selvin, E. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.1.31 · Cited by 5 · cited 1×
“More potent peptides such as liraglutide, semaglutide, and tirzepatide may have greater antiinflammatory effects, consistent with correlations between CRP and weight loss seen in lifestyle interventions and bariatric surgery (20).”
Brodersen, K., Mose, M., Ramer Mikkelsen, U., Jørgensen, J. O. L., Festersen Nielsen, M., Møller, N., Wegeberg, A., Brock, C., Hartmann, B., Holst, J. J., et al. (2022) · Physiological Reports · doi:10.14814/phy2.15462 · Cited by 4
Glucagon-Like Peptide-1 Is Prognostic of Mortality in Acute Respiratory Failure
Hansell, C. E., Aneis, H., Kitsios, G. D., Bain, W., Zhao, Y., Suber, T. L., Evankovich, J. W., Sharma, L., Ramakrishnan, S. K., Prendergast, N. T., et al. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001247 · Cited by 4
Cited by
GLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
“These are likely mediated in large part by the pleiotropic antiinflammatory effects of GLP-1RAs (147).”
Voros, C., Chatzinikolaou, F. G., Papapanagiotou, I., Polykalas, S., Mavrogianni, D., Koulakmanidis, A.-M., Athanasiou, D., Kanaka, V., Bananis, K., Athanasiou, A. I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020759 · Cited by 34
“Activation of GLP-1R in adipocytes inhibits the activity of pro-inflammatory cytokines such as TNF-α and IL-6, while initiating lipolysis, browning, and the secretion of adiponectin [6].”
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 20
GEORGAKOPOULOU, V. E., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100449 · Cited by 10
“Importantly, several of these effects have been observed in experimental settings that minimize or exclude weight change, supporting the existence of weight-independent pulmonary mechanisms [29].”
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Metadata
- Authors
- Wong, C. K., & Drucker, D. J.
- Affiliations
- Lunenfeld-Tanenbaum Research Institute (CA)
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Journal of Clinical Investigation
- Published
- 2025-11-03
- Volume
- 135
- Issue
- 21
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC12578379
- OpenAlex
- W4415855223
- Semantic Scholar
- 4076facbe68bf6ad70262f15cb231a58eed3a21f
- Cited by
- 112
- References
- 92
- Citations by year
- 2026: 111 · 2025: 1
- FWCI
- 15.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Diabetes Canada
- Novo Nordisk (154321)
- Canadian Institutes of Health Research (15432_1, 19204)
- Banting and Best Diabetes Centre, University of Toronto (154321)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, GLP-1 receptor signaling, anti-inflammatory activity, inflammation, type 2 diabetes, obesity, cardiovascular disease, chronic kidney disease, metabolic liver disease, arthritis, substance use disorders, neurodegenerative diseases, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Anti-Inflammatory Agents, Diabetes Mellitus, Type 2, Humans, Inflammation, Obesity, Signal Transduction, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.